Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

26 mars 2024 08h00 HE | Source: Healis Therapeutics

Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates of Harvard Medical School to advance clinical-stage neuroscience research

The collaboration will focus on Healis’ clinical program studying the safety and efficacy of CKDB-501A, a BoNT/A neuromodulator, for neuropsychiatry.
27 févr. 2024 08h00 HE | Source: Healis Therapeutics

Healis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea

CKDB-501A, a novel BoNT/A neuromodulator protein, completed a Phase 3 trial to investigate the efficacy and safety in treating the glabella.
12 févr. 2024 08h00 HE | Source: Healis Therapeutics

Healis selected to present at key biotechnology and neuroscience investor conferences in Amsterdam, New York, and San Diego

Healis' clinical program developing BoNT/A neuromodulator proteins has the potential to transform care for over 280 million patients with depression.
02 janv. 2024 08h00 HE | Source: Healis Therapeutics

Healis Therapeutics Announces Supply Agreement with CKD Bio to develop CKDB-501 for neuropsychiatric indications

NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, today announced it has entered into a supply agreement with CKD Bio Corporation...